As injectable drugs continue to expand across therapeutic areas, designing patient-centric clinical trials is critical for success. This article explores the intersection of formulation science and device design – highlighting how formulation development and advanced autoinjector platforms like Jabil’s Qfinity+™ autoinjector can improve patient experience, adherence, and outcomes. Key formulation and usability factors such as excipient selection, viscosity, administration force, and usability testing are discussed in the context of clinical trial design and patient engagement. 

Injectable drug development is experiencing a profound shift toward patient-centricity, reshaping how therapies are formulated, delivered, and regulated. One of the most notable trends is the rise of self-administered injectable therapies. Driven by the growth of biologics and the increasing need for chronic disease management outside traditional healthcare settings, patients are seeking treatments that fit into their daily lives. Pharmaceutical companies are responding with safety syringe devices, autoinjectors, which commonly comprise a pre-filled syringe, and wearable devices designed to simplify administration and improve adherence.